EUVIMEDEUVIMED entdecken
Crossref

Kudzu resistant starch effectively ameliorates non‐alcoholic fatty liver disease by protecting the gut microbiota intestinal barrier and suppressing inflammatory responses

Huanhuan Dong, Xunyue Yang iD, Ying Zhou, Mei Yang, Hua Zhang, Xiaoru Liu, Weifeng Zhu

Journal of the Science of Food and Agriculture · 2025-09 · 105 (12) · 6538-6555

DOI: 10.1002/jsfa.14371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, online erschienen am 25.06.2025. Verfasst von Huanhuan Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Pueraria, Resistant Starch. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program Key Special Project, China, Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Non‐alcoholic fatty liver disease (NAFLD), including non‐alcoholic steatohepatitis, may lead to a cocktail of disease consequences, for instance, type II diabetes, liver fibrosis, and even hepatocarcinogenesis. The complex pathogenesis of NAFLD results in a shortage of an effective drug for its treatment. Currently, a healthy diet and regular exercise are considered one of the most effective and safe ways to mitigate NAFLD as well as other types of metabolic disorders. Kudzu‐resistant starch (KRS) has developed as a potential dietary supplement attributed to its prebiotic properties, particularly its ability to regulate gut microbiota and intestinal barrier function. This study discusses the alleviative effects of KRS on high‐fat diet and dextran sulfate sodium induced intestinal barrier dysfunction, inflammation, gut microbial dysbiosis, and liver steatosis. RESULTS The results identified KRS has ameliorated intestinal barrier dysfunction by increasing the expression of zonula occludens‐1 (ZO‐1) and mucin 2 (Muc2). Furthermore, it also down‐regulated the gut‐derived LPS/TLR4 signaling pathway, dramatically alleviating inflammatory responses, including serum, colon, and liver tumor necrosis factor‐ α (TNF‐ α ), interleukin‐6 (IL‐6), and monocyte chemotactic protein‐1 (MCP‐1) levels. KRS also had attenuating effects on gut microbiota dysbiosis, restored the gut microbiota abundance and diversity, and increased the butyric acid‐producing bacteria, such as Coprococcus, Bifidobacterium, and Lactobacillus, and it exhibited positive effects in short‐chain fatty acids (SCFAs). KRS attenuated fatty acid‐induced lipid accumulation and regulates lipid metabolism via the sterol regulatory element‐binding protein 1‐c (SREBP‐1c), G‐protein coupled receptors 43 (GPR43), peroxisome proliferator‐activated receptor‐ γ (PPAR‐ γ ), and CCAAT/enhancer‐binding proteins‐ α (C/EBP‐ α ). CONCLUSION The findings reveal that kudzu resistant starch could be a potential supplement for metabolic syndromes, and the efficacy and effectiveness might facilitate the multi‐targeting strategy required to mitigate NAFLD. © 2025 Society of Chemical Industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseasePuerariaResistant StarchStarchIntestinal MucosaAnimalsHumansMiceMaleMice, Inbred C57BLPrebioticsIntestinesDiet, High-FatLiverBacteria

Stichwörter der Autor:innen

intestinal microbiomekudzu‐resistant starchnon‐alcoholic fatty liver disease

Substanzen

Resistant StarchStarchPrebiotics

Autor:innen und Institutionen

  • College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, China.
  • Qingshanhu District Center for Disease Control and Prevention, Nanchang, China.
  • State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, China.

ORCID-Profile: Xunyue Yang

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program Key Special Project, China
  • Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program

Zitieren

APA

Dong, H., Yang, X., Zhou, Y., Yang, M., Zhang, H., Liu, X., & Zhu, W. (2025). Kudzu resistant starch effectively ameliorates non‐alcoholic fatty liver disease by protecting the gut microbiota intestinal barrier and suppressing inflammatory responses. Journal of the Science of Food and Agriculture, 105(12), 6538-6555. https://doi.org/10.1002/jsfa.14371

Vancouver

Dong H, Yang X, Zhou Y, Yang M, Zhang H, Liu X, et al. Kudzu resistant starch effectively ameliorates non‐alcoholic fatty liver disease by protecting the gut microbiota intestinal barrier and suppressing inflammatory responses. Journal of the Science of Food and Agriculture. 2025;105(12):6538-6555. doi:10.1002/jsfa.14371

BibTeX
@article{Dong2025,
  author = {Dong, Huanhuan and Yang, Xunyue and Zhou, Ying and Yang, Mei and Zhang, Hua and Liu, Xiaoru and Zhu, Weifeng},
  title = {Kudzu resistant starch effectively ameliorates non‐alcoholic fatty liver disease by protecting the gut microbiota intestinal barrier and suppressing inflammatory responses},
  journal = {Journal of the Science of Food and Agriculture},
  year = {2025},
  volume = {105},
  number = {12},
  pages = {6538--6555},
  doi = {10.1002/jsfa.14371}
}
Kostenlos starten →